1113 Two drug classes that significantly reduce major adverse cardiovascular events (MACE) and death, regardless of the presence of T2D, are sodiumglucose co-transporter inhibitors (SGLTis) and glucagon-like peptide-1 (GLP-1) receptor agonists (RAs)
Diabetes Care 2015;38:12451252
Advocating for members to enable impactful experiences Using data like social determinants of health, plan sponsor design, member-designated preferences and medical data, we are proactive in the care of members, making sure they feel supported
In completed randomized trials, tirzepatide consistently achieves greater reductions in body weight and HbA1c compared with semaglutide, demonstrating the synergistic metabolic benefits of simultaneous GIP and GLP-1 receptor stimulation
Anxiety or restlessness occasionally accompanies nausea or appetite suppression, especially at higher doses
An independent licensed practitioner reviews your health survey and makes an independent determination